« Back
Home /
Talacotuzumab Biosimilar（Anti-IL-3Ra / CD123 Reference Antibody）

Talacotuzumab Biosimilar（Anti-IL-3Ra / CD123 Reference Antibody）

Item no.	DCC-A262-1mg
Manufacturer	DCChemicals
CASRN	1826831-79-1
Amount	1 mg
Quantity options	100 mg 10 mg 1 mg 5 mg
Specific against	other
Available
Manufacturer - Applications	Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has KDs of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 1 mg

available

Delivery expected until 12/11/2025

Compare

Add to wishlist

Get an offer

Request delivery time